RxDoctor Payments Data

Valerie White

Nurse Practitioner · Danville, VANPI 1831147107

Payments from drug & device makers

$2,969in general payments, 2019–2025

Across 171 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$475
  • AbbVie$463
  • Pfizer$286
  • Merck$132
  • Lilly USA, LLC$128
  • Novartis$108
  • plus $1K from 36 others

What the payments were for

  • Food & beverage$2,969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,969 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$29,751
Medicare patients
98
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate122$119,271
OzempicSemaglutide98$94,159
JardianceEmpagliflozin46$49,529
FarxigaDapagliflozin Propanediol29$36,017
LinzessLinaclotide45$31,056
MounjaroTirzepatide18$27,228
TradjentaLinagliptin15$20,889
EliquisApixaban28$20,770
XareltoRivaroxaban24$18,887
TrulicityDulaglutide11$16,210
Tresiba Flextouch U-200Insulin Degludec17$14,683
MyrbetriqMirabegron18$11,992
JanumetSitagliptin Phos/Metformin Hcl14$8,035
Tresiba Flextouch U-100Insulin Degludec13$6,430
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$4,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$132$127,307136 claims
Novo NordiskOzempic$475$94,15998 claims
Boehringer IngelheimJardiance, Tradjenta$65$70,41961 claims
Lilly USA, LLCMounjaro, Trulicity$128$43,43829 claims
AstraZenecaFarxiga, Symbicort$80$40,09642 claims
AbbVieLinzess$463$31,05645 claims
PfizerEliquis$286$20,77028 claims
Astellas Pharma US IncMyrbetriq$37$11,99218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →